Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia‐propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted to facilitate accurate risk stratification. Previously, we published...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2020
|
| _version_ | 1797094854278250496 |
|---|---|
| author | Hanekamp, D Snel, AN Kelder, A Scholten, WJ Khan, N Metzner, M Irno-Consalvo, M Sugita, M de Jong, A Oude Alink, S Eidhof, H Wilhelm, M Feuring-Buske, M Slomp, J van der Velden, VHJ Sonneveld, E Guzman, M Roboz, GJ Buccisano, F Vyas, P Freeman, S Bachas, C Ossenkoppele, GJ Schuurhuis, GJ Cloos, J |
| author_facet | Hanekamp, D Snel, AN Kelder, A Scholten, WJ Khan, N Metzner, M Irno-Consalvo, M Sugita, M de Jong, A Oude Alink, S Eidhof, H Wilhelm, M Feuring-Buske, M Slomp, J van der Velden, VHJ Sonneveld, E Guzman, M Roboz, GJ Buccisano, F Vyas, P Freeman, S Bachas, C Ossenkoppele, GJ Schuurhuis, GJ Cloos, J |
| author_sort | Hanekamp, D |
| collection | OXFORD |
| description | Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia‐propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted to facilitate accurate risk stratification. Previously, we published the composition of a one‐tube flow cytometric assay, characterised by the presence of 13 important membrane markers for LSC detection. Here we present the validation experiments of the assay in several large AML research centres, both in Europe and the United States. Variability within instruments and sample processing showed high correlations between different instruments (R pearson > 0·91, P < 0·001). Multi‐centre testing introduced variation in reported LSC percentages but was found to be below the clinical relevant threshold. Clear gating protocols resulted in all laboratories being able to perform LSC assessment of the validation set. Participating centres were nearly unanimously able to distinguish LSChigh (>0·03% LSC) from LSClow (<0·03% LSC) despite inter‐laboratory variation in reported LSC percentages. This study proves that the LSC assay is highly reproducible. These results together with the high prognostic impact of LSC load at diagnosis in AML patients render the one‐tube LSC assessment a good marker for future risk classification. |
| first_indexed | 2024-03-07T04:19:47Z |
| format | Journal article |
| id | oxford-uuid:caa04fce-4518-42ba-b0a9-03019f9bd7af |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:19:47Z |
| publishDate | 2020 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:caa04fce-4518-42ba-b0a9-03019f9bd7af2022-03-27T07:08:51ZApplicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre settingJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:caa04fce-4518-42ba-b0a9-03019f9bd7afEnglishSymplectic ElementsWiley2020Hanekamp, DSnel, ANKelder, AScholten, WJKhan, NMetzner, MIrno-Consalvo, MSugita, Mde Jong, AOude Alink, SEidhof, HWilhelm, MFeuring-Buske, MSlomp, Jvan der Velden, VHJSonneveld, EGuzman, MRoboz, GJBuccisano, FVyas, PFreeman, SBachas, COssenkoppele, GJSchuurhuis, GJCloos, JLeukaemic stem cells (LSC) have been experimentally defined as the leukaemia‐propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted to facilitate accurate risk stratification. Previously, we published the composition of a one‐tube flow cytometric assay, characterised by the presence of 13 important membrane markers for LSC detection. Here we present the validation experiments of the assay in several large AML research centres, both in Europe and the United States. Variability within instruments and sample processing showed high correlations between different instruments (R pearson > 0·91, P < 0·001). Multi‐centre testing introduced variation in reported LSC percentages but was found to be below the clinical relevant threshold. Clear gating protocols resulted in all laboratories being able to perform LSC assessment of the validation set. Participating centres were nearly unanimously able to distinguish LSChigh (>0·03% LSC) from LSClow (<0·03% LSC) despite inter‐laboratory variation in reported LSC percentages. This study proves that the LSC assay is highly reproducible. These results together with the high prognostic impact of LSC load at diagnosis in AML patients render the one‐tube LSC assessment a good marker for future risk classification. |
| spellingShingle | Hanekamp, D Snel, AN Kelder, A Scholten, WJ Khan, N Metzner, M Irno-Consalvo, M Sugita, M de Jong, A Oude Alink, S Eidhof, H Wilhelm, M Feuring-Buske, M Slomp, J van der Velden, VHJ Sonneveld, E Guzman, M Roboz, GJ Buccisano, F Vyas, P Freeman, S Bachas, C Ossenkoppele, GJ Schuurhuis, GJ Cloos, J Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting |
| title | Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting |
| title_full | Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting |
| title_fullStr | Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting |
| title_full_unstemmed | Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting |
| title_short | Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting |
| title_sort | applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi centre setting |
| work_keys_str_mv | AT hanekampd applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT snelan applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT keldera applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT scholtenwj applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT khann applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT metznerm applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT irnoconsalvom applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT sugitam applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT dejonga applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT oudealinks applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT eidhofh applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT wilhelmm applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT feuringbuskem applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT slompj applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT vanderveldenvhj applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT sonnevelde applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT guzmanm applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT robozgj applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT buccisanof applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT vyasp applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT freemans applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT bachasc applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT ossenkoppelegj applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT schuurhuisgj applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting AT cloosj applicabilityandreproducibilityofacutemyeloidleukaemiastemcellassessmentinamulticentresetting |